MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Watch Listen Read
Login Nexus Watchlists Settings
  • MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Theme Style
Switch to Dark Mode
BBNX stock logo

BBNX

Beta Bionics, Inc.

$17.05
0.16
 (0.95%)
Exchange:   NASDAQ
Market Cap:   741.166M
Shares Outstanding:  
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Equipment & Services
   
CEO:  Sean T. Saint PE
Full Time Employees:  352
Address: 
11 Hughes
Irvine
CA
92618
US
Website:  https://www.betabionics.com
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

EPS

🔒 You are currently logged out

Login
View full analyst estimates

Earnings Call

🔒 You are currently logged out

Login
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Balance Sheet

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Cash Flow Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Analyst Estimates

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Current Key Metrics

🔒 You are currently logged out

Login

Forward P/E Ratios

🔒 You are currently logged out

Login

SWOT Analysis

🔒 You are currently logged out

Login

At what price to buy it? –
Intrinsic Value Calculator


Calculate BBNX Intrinsic Value

🔒 You are currently logged out

Login
MS_Stock_Embed class not found. Please check plugin configuration.

Relevant news